Clinical trial • Psychiatry
MELATONIN for Psychiatric disorder | Insomnia
Clinical trial of MELATONIN for Psychiatric disorder | Insomnia.
Overview
- Trial Therapeutic Area
- Psychiatry
- Trial Disease
- Psychiatric disorder | Insomnia
- Drug Modality
- Small molecule | Small molecule | Other
- Paediatric Trial
- Yes
Key dates
- Initial CTIS Submission Date
- 03-01-2025
- First CTIS Authorization Date
- 14-04-2025
Trial design
Randomised, melatonin (melatonin orifarm 3 mg film-coated tablets; product strength 3 mg, max daily dose listed as 9 mg) versus low-dose quetiapine (quetiapin sandoz 25 mg film-coated tablets; product strength 25 mg, max daily dose listed as 150 mg) versus placebo (starch and lactose containing gelatine capsules). specific dosing schedules/frequency in-protocol not specified in ctis summary.-controlled trial across 1 site in Denmark.
- Randomised
- Yes
- Comparator
- Melatonin (Melatonin Orifarm 3 mg film-coated tablets; product strength 3 mg, max daily dose listed as 9 mg) versus low-dose quetiapine (Quetiapin Sandoz 25 mg film-coated tablets; product strength 25 mg, max daily dose listed as 150 mg) versus placebo (Starch and Lactose containing gelatine capsules). Specific dosing schedules/frequency in-protocol not specified in CTIS summary.
- Target Sample Size
- 255
Eligibility
Recruits 255 paediatric patients.
- Pregnancy Exclusion
- Women of childbearing potential: negative pregnancy test at baseline and use of highly effective contraception measures
- Vulnerable Population
- Includes adolescents (16-17 years). Informed consent must be provided by both the minor and the legally designated representative (consent/assent handling specified). The CTIS record lists subject information and consent documents for parents and youths (e.g. L1_Flles samtykkeerklring til forldre og unge; L2_Forldrefuldmagt; L1_SIS_unge; L1_SIS_forldre). The trial population is not flagged as 'vulnerable' in the CTIS population selection (isVulnerablePopulationSelected: false).
Inclusion criteria
- {"criterion_text":"- 16 to 17 years of age\n- ICD-10 diagnosis of a current or previous mental or behavioral disorder (F20-F69, F84, F90-F95)\n- For the diagnoses F84 and F90 a previous period of treatment with melatonin is required\n- Self-reported sleep difficulties at least three times per week in the preceding 3 months\n- Insomnia Severity Index score ≥11\n- Non-pharmacological treatment options including sleep hygiene education, weighted blanket or other gravity products have been tested with insufficient effect\n- Women of childbearing potential: negative pregnancy test at baseline and use of highly effective contraception measures\n- Informed consent provided by both the minor and the legally designated representative"}
Exclusion criteria
- {"criterion_text":"- Current treatment with melatonin or quetiapine\n- Severe somatic comorbidity\n- BMI ≥ 35 kg/m2\n- Breastfeeding\n- Alcohol and/or substance dependency (F1X.2) within the last 3 months\n- Inadequate Danish language skills\n- Not able to make an informed consent\n- Increased cardiac risk as assessed by presence of cardiac risk factors, cardiac symptoms, or prolonged QT-interval at baseline electrocardiogram (ECG)"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Insomnia severity using the Insomnia Severity Index (ISI)","definition_or_measurement_approach":"Measured using the Insomnia Severity Index (ISI)."}
Secondary endpoints
- {"endpoint_text":"- Clinical global impression (CGI)","definition_or_measurement_approach":"Measured using the Clinical Global Impression (CGI) scale."}
- {"endpoint_text":"- Subjective sleep quality using the Pittsburgh Sleep Quality Index (PSQI)","definition_or_measurement_approach":"Measured using the Pittsburgh Sleep Quality Index (PSQI)."}
- {"endpoint_text":"- Psychosocial functioning using the Personal and Social Performance Scale (PSP)","definition_or_measurement_approach":"Measured using the Personal and Social Performance Scale (PSP)."}
- {"endpoint_text":"- Patient-reported subjective well-being using the WHO-5 well-being index","definition_or_measurement_approach":"Measured using the WHO-5 well-being index."}
- {"endpoint_text":"- Rest-sleep-activity cycles and physiological variables","definition_or_measurement_approach":"Rest-sleep-activity cycles and physiological variables (measurement approach not specified in CTIS record)."}
Recruitment
- Registry Or Advocacy Recruitment
- True: forskningNU | forsoegstjenestenDK | forsoegspersonDK
- Digital Remote Recruitment
- True: online announcements/advertisements on research volunteer portals (forskningNU, forsoegstjenestenDK, forsoegspersonDK) as indicated by recruitment material titles.
- Planned Sample Size
- 255
- Recruitment Window Months
- 49
- Consent Approach
- Informed consent must be provided by both the minor and the legally designated representative. CTIS lists subject information and consent forms for parents and youths (examples: L1_Flles samtykkeerklring til forldre og unge; L1_SIS_unge; L1_SIS_forldre; L2_Forldrefuldmagt). An adult consent form ('L1_ICF_Samtykkeerklring voksne') is also present in documents.
Methods
- Plakat A3 (recruitment poster) — indicated by document title 'K2_ Recruitment material_Plakat A3' (channel: poster; target audience: adolescents and parents in Denmark).
- Online advertisement to research volunteer portals — indicated by document title 'K2_Recruitment material_Annonce til forskningNU forsoegstjenestenDK og forsoegspersonDK' (channels: online research volunteer portals; target audience: adolescents/parents in Denmark).
- Leaflet A5 — indicated by document title 'K2_ Recruitment material_Pjece A5' (channel: leaflet/brochure; target audience: adolescents and parents in Denmark).
- Recruitment arrangements document 'K1_ Recruitment arrangements' (procedural recruitment arrangements; country: Denmark).
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 255
Denmark
- Earliest CTIS Part Ii Submission Date
- 21-03-2025
- Latest Decision Or Authorization Date
- 14-04-2025
- Processing Time Days
- 24
- Number Of Sites
- 1
- Number Of Participants
- 255
Sites
- Site Name
- Psykiatrisk Center Kobenhavn
- Department Name
- Bispebjerg
- Principal Investigator Name
- Lone Baandrup
- Principal Investigator Email
- Lone.Baandrup@regionh.dk
- Contact Person Name
- Lone Baandrup
- Contact Person Email
- Lone.Baandrup@regionh.dk
- Number Of Participants
- 255
Sponsor
Primary sponsor
- Full Name
- Psykiatrisk Center Kobenhavn
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"sponsorDuties code 1","organisation_type":"Hospital/Clinic/Other health care facility"}
Investigational products
- Investigational Product Name
- Melatonin Orifarm 3 mg filmdragerade tabletter
- Active Substance
- MELATONIN
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Authorisation Status
- Marketing authorisation information present (prodAuthStatus: 2; euMpNumber PRD11434328; authorisation country: SE)
- Maximum Dose
- 9 mg daily
- Investigational Product Name
- Quetiapin Sandoz 25 mg filmdrasjerte tabletter
- Active Substance
- QUETIAPINE
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Authorisation Status
- Marketing authorisation information present (prodAuthStatus: 2; euMpNumber PRD2233998; authorisation country: NO)
- Maximum Dose
- 150 mg daily
- Investigational Product Name
- Starch and Lactose containing gelatine capsules
- Modality
- Other
Related trials
Other published trials that may interest you.